Search

Displaying results 6181 - 6190 of 8974 in total
  1. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  2. Drug

    Tiapride

    go.drugbank.com/drugs/DB13025
    Investigational

    Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain.

  3. Drug

    LX-7101

    go.drugbank.com/drugs/DB16009
    Investigational

    LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).

  4. Drug

    Fontolizumab

    go.drugbank.com/drugs/DB05111
    Investigational

    Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.

  5. Drug

    Creatinolfosfate

    go.drugbank.com/drugs/DB13071
    Investigational

    COP has been investigated for the treatment of Diabetic Retinopathy. … COP is under investigation for the treatment of Rheumatoid Arthritis, Mature B-Cell Lymphoma, and Noninflammatory Degenerative Joint Disease.

  6. Drug

    Squalene

    go.drugbank.com/drugs/DB11460
    ApprovedInvestigationalVet approvedWithdrawn

    It is not susceptible to lipid peroxidation and provides skin protection.

  7. Drug

    RGX-121

    go.drugbank.com/drugs/DB17681
    Investigational

    RGX-121 is designed to use the NAV AAV9 vector to deliver the human iduronate-2-sulfatase gene to the central nervous system.

  8. Drug

    Tyloxapol

    go.drugbank.com/drugs/DB06439
    ApprovedInvestigational

    Tyloxapol is a non-ionic detergent often used as a surfactant.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    AER001

    go.drugbank.com/drugs/DB05078
    Investigational

    AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.

  10. Drug

    Eptotermin alfa

    go.drugbank.com/drugs/DB11631
    ApprovedWithdrawn

    A bone morphogenetic protein that is widely expressed during EMBRYONIC DEVELOPMENT. It is both a potent osteogenic factor and a specific regulator of nephrogenesis. Eptotermin alfa is an ingredient in the EMA-withdrawn product Osigraft.

    Categories: Drugs for Treatment of Bone Diseases